CDK9 inhibitors for the treatment of solid tumors

被引：3

作者：

Mo, Christiana ^{[1
,2
]}

Wei, Ning ^{[1
,2
,3
]}

Li, Terence ^{[1
,2
,3
]}

Bhat, Muzaffer Ahmed ^{[1
,2
,3
]}

Mohammadi, Mahshid ^{[1
,2
,3
]}

Kuang, Chaoyuan ^{[1
,2
,3
]}

机构：

[1] Montefiore Einstein, Dept Oncol, Bronx, NY 10461 USA

[2] Montefiore Einstein Comprehens Canc Ctr, Bronx, NY USA

[3] Montefiore Einstein, Dept Mol Pharmacol, Bronx, NY USA

来源：

BIOCHEMICAL PHARMACOLOGY | 2024年 / 229卷

关键词：

CDK9; Cancer therapeutics; Targeted therapy; Solid tumors; CYCLIN-DEPENDENT KINASE; CANCER STEM-CELLS; GENE COPY NUMBER; TRANSCRIPTION ELONGATION; TARGETING CDK9; PANCREATIC-CANCER; PHASE-I; P-TEFB; EXPRESSION; RECEPTOR;

D O I：

10.1016/j.bcp.2024.116470

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cyclin-dependent kinase 9 (CDK9) regulates mRNA transcription by promoting RNA Pol II elongation. CDK9 is now emerging as a potential therapeutic target for cancer, since its overexpression has been found to correlate with cancer development and worse clinical outcomes. While much work on CDK9 inhibition has focused on hematologic malignancies, the role of this cancer driver in solid tumors is starting to come into focus. Many solid cancers also overexpress CDK9 and depend on its activity to promote downstream oncogenic signaling pathways. In this review, we summarize the latest knowledge of CDK9 biology in solid tumors and the studies of small molecule CDK9 inhibitors. We discuss the results of the latest clinical trials of CDK9 inhibitors in solid tumors, with a focus on key issues to consider for improving the therapeutic impact of this drug class.

引用

页数：17

共 157 条

[1] ERK2 stimulates MYC transcription by anchoring CDK9 to the MYC promoter in a kinase activity-independent manner [J].

Agudo-Ibanez, Lorena ;

Morante, Marta ;

Garcia-Gutierrez, Lucia ;

Quintanilla, Andrea ;

Rodriguez, Javier ;

Munoz, Alberto ;

Leon, Javier ;

Crespo, Piero .

SCIENCE SIGNALING, 2023, 16 (794)

[2] CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia [J].

Ajiro, Masahiko ;

Sakai, Hiroyuki ;

Onogi, Hiroshi ;

Yamamoto, Makoto ;

Sumi, Eriko ;

Sawada, Teruo ;

Nomura, Takashi ;

Kabashima, Kenji ;

Hosoya, Takamitsu ;

Hagiwara, Masatoshi .

CLINICAL CANCER RESEARCH, 2018, 24 (18) :4518-4528

[3] A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma [J].

Al Emran, Abdullah ;

Tseng, Hsin-Yi ;

Gunatilake, Dilini ;

Cook, Stuart J. ;

Ahmed, Farzana ;

Wang, Shudong ;

Hersey, Peter ;

Gallagher, Stuart J. ;

Tiffen, Jessamy C. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (09) :2238-+

[4] Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor [J].

Albert, T. K. ;

Rigault, C. ;

Eickhoff, J. ;

Baumgart, K. ;

Antrecht, C. ;

Klebl, B. ;

Mittler, G. ;

Meisterernst, M. .

BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) :55-68

[5] Targeting Autophagy in Cancer: Recent Advances and Future Directions [J].

Amaravadi, Ravi K. ;

Kimmelman, Alec C. ;

Debnath, Jayanta .

CANCER DISCOVERY, 2019, 9 (09) :1167-1181

[6] An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia [J].

Anshabo, Abel Tesfaye ;

Bantie, Laychiluh ;

Diab, Sarah ;

Lenjisa, Jimma ;

Kebede, Alemwork ;

Long, Yi ;

Heinemann, Gary ;

Karanjia, Jasmine ;

Noll, Benjamin ;

Basnet, Sunita K. C. ;

Li, Manjun ;

Milne, Robert ;

Albrecht, Hugo ;

Wang, Shudong .

CANCERS, 2022, 14 (05)

[7] CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents [J].

Anshabo, Abel Tesfaye ;

Milne, Robert ;

Wang, Shudong ;

Albrecht, Hugo .

FRONTIERS IN ONCOLOGY, 2021, 11

[8] Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets [J].

Balko, Justin M. ;

Giltnane, Jennifer M. ;

Wang, Kai ;

Schwarz, Luis J. ;

Young, Christian D. ;

Cook, Rebecca S. ;

Owens, Phillip ;

Sanders, Melinda E. ;

Kuba, Maria G. ;

Sanchez, Violeta ;

Kurupi, Richard ;

Moore, Preston D. ;

Pinto, Joseph A. ;

Doimi, Franco D. ;

Gomez, Henry ;

Horiuchi, Dai ;

Goga, Andrei ;

Lehmann, Brian D. ;

Bauer, Joshua A. ;

Pietenpol, Jennifer A. ;

Ross, Jeffrey S. ;

Palmer, Gary A. ;

Yelensky, Roman ;

Cronin, Maureen ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Arteaga, Carlos L. .

CANCER DISCOVERY, 2014, 4 (02) :232-245

[9] The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508 [J].

Baumli, Sonja ;

Hole, Alison J. ;

Noble, Martin E. M. ;

Endicott, Jane A. .

ACS CHEMICAL BIOLOGY, 2012, 7 (05) :811-816

[10] CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity [J].

Bhutada, Isha ;

Khambati, Fatema ;

Cheng, Shi-Yuan ;

Tiek, Deanna M. ;

Duckett, Derek ;

Lawrence, Harshani ;

Vogelbaum, Michael A. ;

Mo, Qianxing ;

Chellappan, Srikumar P. ;

Padmanabhan, Jaya .

NEURO-ONCOLOGY, 2024, 26 (01) :70-84

← 1 2 3 4 5 6 7 8 9 10 →